Aurora Continues Accelerated Growth
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 2, 2016) - Aurora Cannabis Inc. ("Aurora" or the "Company") (CSE:ACB)(OTCQB: ACBFF)(FRANKFURT:21P) (WKN: A1C4WM) is pleased to announce that its wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., a producer and distributor of medicinal cannabis pursuant to the Marihuana for Medical Purposes Regulations ("MMPR"), has registered hundreds of fully authorized medical cannabis clients, crop yields have proven to be 100 percent more productive than forecasted, and the strain selection will expand rapidly this month.
Aurora's recent crop yielded 1.36 grams per watt, or 1.4 kilograms (3.08 pounds) per light. The facility, with 55,200 square feet of expandable licensed production space, will be running at full capacity by spring 2016, with a demonstrated capability of producing over 7,000 kg of dried cannabis annually.
Furthermore, the Company recently launched its revamped website at www.AuroraMJ.com with a streamlined registration process and user-friendly patient and physician portals. Registrations began January 4th, 2016, with all Aurora strains being priced at $8 per gram, as well as a $5 per gram compassionate pricing standard across all strains.
Three-hundred and ten people became a part of Aurora's 'Founding 420' in the month of January. Each member of the Founding 420 represents one of the Company's first four-hundred and twenty clients. This bestows upon each member a number of benefits, including a welcome package with an Aurora-branded DaVinci Ascent portable vaporizer, a premium Aurora grinder, free cross-country shipping, and $50 in Aurora credit. In return, Aurora will be asking for detailed feedback with respect to the product, the service, the delivery, our brand and other key metrics.
Neil Belot, Chief Brand Officer, comments, "People have been eagerly waiting to experience the Aurora Standard, and the response from the community has been fantastic. The Founding 420 welcome package has been a big hit and everyone is wondering what we are up to for our next campaign; here is a hint - 710."
Over the next several months, one of Aurora's future strains availabile is poised to make global headlines. Facility Director, Joel Fuzat, explains why:
"In February 2016, Aurora intends to begin selling its flagship CBD cannabis strain. This groundbreaking development represents new heights in the field of medicinal marijuana in Canada. Our CBD-rich strain tested at over 25% CBD and just 1% THC by an independent third-party laboratory during the qualification run, which would make this the highest percentage CBD flower in Canada by a significant margin."
Cannabidiol, also known as CBD, is a non-pyschoactive cannabinoid. To date, according to various medical studies it has shown promise as a treatment for chronic pain, seizures, epilepsy, multiple, sclerosis, anxiety, different forms of inflammation, and regulation of immune system functioning amongst others. Further studies are underway to explore its promise as an inhibitor of cancer cell growth.
Additionally, Aurora's application for a Section 56 exemption to produce cannabis derivatives, such as CBD oil products, has been submitted to Health Canada for approval. In anticipation of the introduction of this new suite of products, Mr. Bryan Pyle, an expert in chromatographic separation and extraction, has been added to the Aurora team.
Aurora CEO, Terry Booth, says, "We are thrilled to have Bryan join us. His experience in high value plant metabolites is invaluable. Bryan will help to ensure standardization and consistency in all our extract-based products. The Aurora Standard continues to resonate with people and raise the bar for the industry as a whole."
Terry Booth also commented, "Now that we shored up our cash position, we can execute on a number of key initiatives that will swiftly strengthen market share and likely bring us to profitability in the shortest time frame accomplished by any publicly traded Licensed Producer in the MMPR industry to date."
About Aurora Cannabis Inc.
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada. Aurora's wholly-owned subsidiary, Australis Capital Inc., is an active participant in the U.S. Cannabis market. Aurora is trading on the Canadian Securities Exchange under the trading symbol "ACB".
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
This news release contains statements about the Company's expectations regarding production capacity, production yields and other aspects of its anticipated future operations that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Such factors include but are not limited to the Company's ability to obtain the necessary financing and the general impact of financial market conditions, the yield from marijuana growing operations, product demand, changes in prices of required commodities, competition, government regulations and other risks set out in the Company's management's discussion and analysis filed on SEDAR. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.
FOR FURTHER INFORMATION PLEASE CONTACT:
Director of Business Development